CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:CLCD
- CUSIP: N/A
- Web: www.colucid.com
Average Prices:- 50 Day Moving Avg: $44.95
- 200 Day Moving Avg: $33.88
- 52 Week Range: $5.26 - $46.65
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -25.85
- P/E Growth: 0.000
Profitability:- Return on Equity: -83.51%
- Return on Assets: -70.62%
Debt:- Current Ratio: 11.31%
- Quick Ratio: 11.30%
Misc:- Average Volume: 543,728 shs.
- Beta: 1.51
Frequently Asked Questions for CoLucid Pharmaceuticals (NASDAQ:CLCD)
What is CoLucid Pharmaceuticals' stock symbol?
CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."
How were CoLucid Pharmaceuticals' earnings last quarter?
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) issued its earnings results on Wednesday, November, 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.79). View CoLucid Pharmaceuticals' Earnings History.
Where is CoLucid Pharmaceuticals' stock going? Where will CoLucid Pharmaceuticals' stock price be in 2017?
6 brokerages have issued 12-month target prices for CoLucid Pharmaceuticals' shares. Their forecasts range from $40.00 to $57.00. On average, they expect CoLucid Pharmaceuticals' stock price to reach $48.10 in the next twelve months. View Analyst Ratings for CoLucid Pharmaceuticals.
What are analysts saying about CoLucid Pharmaceuticals stock?
Here are some recent quotes from research analysts about CoLucid Pharmaceuticals stock:
- 1. Piper Jaffray Companies analysts commented, "We see this announcement as resulting from CoLucid's clean design and execution of its Phase III program for oral lasmiditan, and expect the second Phase III SPARTAN trial to read out on schedule in 3Q17. On the GLADIATOR open-label study, we believe that retention rates remain at >70% and that Lilly has likely performed thorough diligence on ongoing safety, efficacy, and compliance in the program. Therefore we see relatively low risk to new information arising in the near-term which threatens completion of this transaction. Overall, the bid confirms our long-held thesis around clinical value of a new acute migraine treatment that provides advantages over standard-of-care triptans on CV safety as well as efficacy for some patients. At this time, we are reducing our rating for CLCD to Neutral." (1/18/2017)
- 2. According to Zacks Investment Research, "CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company's product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts. " (1/10/2017)
Who are some of CoLucid Pharmaceuticals' key competitors?
Some companies that are related to CoLucid Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Company (MRK), Sanofi (SNY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Theravance Biopharma (TBPH), Horizon Pharma PLC (HZNP), Pacira Pharmaceuticals (PCRX) and Innoviva (INVA).
When did CoLucid Pharmaceuticals IPO?
(CLCD) raised $55 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,500,000 shares at $10.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and William Blair was co-manager.
How do I buy CoLucid Pharmaceuticals stock?
Shares of CoLucid Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CoLucid Pharmaceuticals' stock price today?
One share of CoLucid Pharmaceuticals stock can currently be purchased for approximately $46.53.
MarketBeat Community Rating for CoLucid Pharmaceuticals (NASDAQ CLCD)MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $48.10 (3.39% upside) |
Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/23/2017 | Barclays PLC | Downgrade | Overweight -> Equal Weight | $45.00 | N/A |  |
| 1/18/2017 | BTIG Research | Set Price Target | Buy | $52.00 | N/A | |
| 1/18/2017 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
| 1/18/2017 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | $49.00 -> $46.50 | N/A | |
| 10/24/2016 | Stifel Nicolaus | Boost Price Target | Buy | $30.00 -> $40.00 | N/A | |
| 9/19/2016 | Ladenburg Thalmann Financial Services | Set Price Target | Buy | $57.00 | N/A | |
(Data available from 6/22/2015 forward)
Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)Earnings History by Quarter for CoLucid Pharmaceuticals (NASDAQ CLCD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2016 | 9/30/2016 | ($0.79) | ($0.79) | | | View | N/A | |
| 8/10/2016 | Q2 | ($0.84) | ($1.06) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.73) | ($0.85) | | | View | N/A | |
| 3/2/2016 | Q4 2015 | ($0.64) | ($0.74) | | | View | N/A | |
| 11/10/2015 | Q3 | ($0.63) | ($0.59) | | | View | N/A | |
| 8/12/2015 | Q2 2015 | ($0.40) | ($1.17) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)Current Year EPS Consensus Estimate: $-3.460 EPS
Next Year EPS Consensus Estimate: $-1.800 EPS
Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CoLucid Pharmaceuticals (NASDAQ:CLCD)Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 64.17%
Insider Trades by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/5/2017 | Linda C Hogan | Insider | Sell | 2,580 | $35.18 | $90,764.40 | |
| 1/5/2017 | Thomas P Mathers | CEO | Sell | 1,502 | $34.78 | $52,239.56 | |
| 1/3/2017 | Bernice Kuca | Insider | Sell | 772 | $36.25 | $27,985.00 | |
| 1/3/2017 | Matthew D Dallas | CFO | Sell | 1,473 | $36.25 | $53,396.25 | |
| 12/5/2016 | Linda C Hogan | Insider | Sell | 2,583 | $37.77 | $97,559.91 | |
| 12/5/2016 | Thomas P. Mathers | CEO | Sell | 1,502 | $38.75 | $58,202.50 | |
| 12/1/2016 | Bernice Kuca | Insider | Sell | 772 | $35.22 | $27,189.84 | |
| 12/1/2016 | Matthew D. Dallas | CFO | Sell | 1,473 | $35.17 | $51,805.41 | |
| 11/7/2016 | Linda C Hogan | Insider | Sell | 1,862 | $28.56 | $53,178.72 | |
| 11/7/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $28.57 | $42,912.14 | |
| 11/1/2016 | Linda C Hogan | Insider | Sell | 719 | $30.00 | $21,570.00 | |
| 10/5/2016 | Linda C Hogan | Insider | Sell | 2,581 | $37.22 | $96,064.82 | |
| 10/5/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $37.08 | $55,694.16 | |
| 9/14/2016 | Thomas P Mathers | CEO | Sell | 6,000 | $23.32 | $139,920.00 | |
| 9/9/2016 | A/S Novo | Major Shareholder | Buy | 100,000 | $20.00 | $2,000,000.00 | |
| 9/7/2016 | Thomas P Mathers | CEO | Sell | 6,502 | $21.72 | $141,223.44 | |
| 9/6/2016 | Linda C Hogan | Insider | Sell | 48,736 | $19.87 | $968,384.32 | |
| 8/31/2016 | Raymond Skwierczynski | Insider | Sell | 150 | $10.86 | $1,629.00 | |
| 8/19/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.41 | $4,272.28 | |
| 8/10/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.30 | $4,216.40 | |
| 8/5/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $8.31 | $12,481.62 | |
| 8/3/2016 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 153,028 | $8.45 | $1,293,086.60 | |
| 7/29/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $9.09 | $4,617.72 | |
| 7/20/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.97 | $4,556.76 | |
| 7/11/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $9.10 | $4,622.80 | |
| 6/30/2016 | Raymond Skwierczynski | Insider | Sell | 516 | $7.01 | $3,617.16 | |
| 6/20/2016 | Raymond Skwierczynski | Insider | Sell | 1,008 | $6.80 | $6,854.40 | |
| 6/6/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $7.25 | $10,889.50 | |
| 4/28/2016 | Vi Associates L.P. Dp | Major Shareholder | Sell | 235 | $6.96 | $1,635.60 | |
| 8/25/2015 | Thomas P Mathers | CEO | Buy | 7,500 | $7.10 | $53,250.00 | |
| 5/11/2015 | A/S Novo | Major Shareholder | Buy | 1,300,000 | $10.00 | $13,000,000.00 | |
| 5/11/2015 | Arthur M Pappas | Director | Buy | 300,000 | $10.00 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
| Source: |
|
| Date | Headline |
|---|
 | Lilly Completes Acquisition of CoLucid Pharmaceuticals
finance.yahoo.com - June 7 at 7:09 PM |
 | An experimental treatment for migraines just passed a critical study
www.businessinsider.com - May 12 at 9:56 PM |
 | 5 Top Technology Investments To Make In 2017
www.nasdaq.com - May 11 at 4:57 PM |
 | CoLucid Pharmaceuticals (CLCD) Getting Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 28 at 12:42 PM |
| CoLucid Pharmaceuticals (CLCD) Receives Daily News Impact Score of 0.44
www.americanbankingnews.com - April 18 at 2:20 PM |
| CoLucid Pharmaceuticals Inc (CLCD) Cut to "Equal Weight" at Barclays PLC
www.americanbankingnews.com - April 9 at 3:46 PM |
| CoLucid Pharmaceuticals Inc (CLCD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 12:38 PM |
| Andreas Halvorsen Sells Amazon, MasterCard in 4th Quarter
finance.yahoo.com - March 19 at 11:47 AM |
 | Eli Lilly & Co. (LLY) Completes Takeover of CoLucid Pharmaceuticals (CLCD) - StreetInsider.com
www.streetinsider.com - March 1 at 9:24 PM |
| COLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delis
biz.yahoo.com - March 1 at 9:24 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders
finance.yahoo.com - February 2 at 4:39 PM |
 | Bragar Eagel & Squire, P.C. Is Investigating the Board …
uk.finance.yahoo.com - January 31 at 9:47 PM |
| Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - January 31 at 9:47 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - January 31 at 4:45 PM |
 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional ...
www.businesswire.com - January 30 at 10:14 PM |
| INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - January 30 at 10:14 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - January 27 at 5:44 PM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional ...
www.businesswire.com - January 23 at 4:37 PM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - January 23 at 4:37 PM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - January 23 at 4:37 PM |
 | SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM |
| COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM |
| COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company
finance.yahoo.com - January 20 at 5:30 PM |
| CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in ... - PR Newswire (press release)
www.prnewswire.com - January 19 at 10:35 PM |
| Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M - StreetInsider.com
www.streetinsider.com - January 19 at 10:34 PM |
 | CoLucid Pharmaceuticals Inc. (CLCD) Leaped To A New High On Merger News
www.rttnews.com - January 19 at 5:33 PM |
CoLucid Pharmaceuticals (CLCD) Chart for Thursday, June, 22, 2017
